2 June 2009
ECO Animal Health Group plc
ECO RECEIVES FURTHER APPROVAL
FOR AIVLOSIN®
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO
Animal Health Limited (ECO) has been granted registration approval from the
European Commission to commence marketing its Aivlosin® 625 mg/g granules for
oral solution for medicated drinking water for pigs. This marketing approval is
the final step in the approval process and follows the positive opinion from the
Committee for Medicinal Products for Veterinary Use (CVMP) of the European
Medicines Agency (EMEA) which we announced on 18 March 2009. ECO expects to
commence marketing in early Autumn 2009.
This new pan-European approval is in addition to the current European
authorisations for the Aivlosin® product portfolio for use in pigs and poultry.
This presentation of Aivlosin®, ECO's patented macrolide antibiotic, will be
marketed for the treatment and prevention of ileitis (porcine proliferative
enteropathy (PPE)), a market segment estimated to be worth in the region of US
$30 million per annum at manufacturer level.
Aivlosin® granules for oral solution dissolve readily in drinking water
providing a simple solution for the accurate and simultaneous treatment of large
numbers of pigs.
Peter Lawrence, Chairman of ECO Animal Health Group plc, commented:
"This is a very important approval and marks further progress in ECO's
continuing development of Aivlosin® as a global veterinary product. It will
significantly extend the sales and marketing reach of Aivlosin®"
Contacts:
ECO Animal Health Group plc Marc Loomes 020 8447
8899
Spiro Financial Anthony Spiro 020 8336
6196
Cenkos Securities plc Stephen Keys 020
7397 8926
(Nominated Adviser) Liz
Bowman 020 7397 8928
ECO Animal Health Group plc is a leader in the development, registration and
marketing of pharmaceutical products for animals. Our products for these global
growth markets promote well-being. Our financial goals are achieved through the
careful and responsible application of science to generate value for our
shareholders.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.